50625-94-0

Upstream product

• 120-47-8 Ethyl 4-hydroxybenzoate 
• 106-89-8 epichlorohydrin 
• 99-96-7 4-hydroxy-benzoic acid 

Downstream Products

• 57554-43-5 4-(2-hydroxy-3-isopropylamino-propoxy)-benzoic acid ethyl ester 
• 104343-41-1 8-<<2-hydroxy-3-(p-ethoxycarbonyl)phenoxypropyl>thio> adenosine 
• 36116-09-3 C₂₁H₂₄O₇ 
• 147538-72-5 2-[3-[(p-ethyloxycarbonyl)-phenoxy]-2-hydroxy-propylthio]-benzothiazole 
• 104343-40-0 6-amino-8-{[[3-(4-ethoxycarbonyl)phenoxy-2-hydroxy]propyl]-thio}purine 
• 35217-95-9 4-(oxiran-2-ylmethoxy)benzoic acid 
• 147538-77-0 2-[3-[(p-ethyloxycarbonyl)-phenoxy]-2-hydroxy-propylthio]-benzoxazole 

Relevant academic research and scientific papers

Renewable resource-based epoxy resins derived from multifunctional poly(4-hydroxybenzoates)

Herein we report on the preparation and cure of epoxy resins derived from renewable resources such as 4-hydroxybenzoic acid, glycerol, pentaerythritol, dipentaerythritol, trimethylolpropane, and sorbitol, aiming at substituting bisphenol A-based epoxy res

8-Substituted purine derivatives: a new class of lipid-lowering agents

A series of purine derivatives have been prepared and their in vivo abilities to lower plasma total cholesterol and triglyceride levels, and to elevate high density lipoprotein (HDL) cholesterol levels in hyperlipemic rats have been tested.Some compounds, among which 8-propylthio>adenosine 31, 8--2-oxopropylthio>adenosine 33 and 8--2-hydrazonecarboxamidepropylthio>adenosine 36 appear to be the most interesting, have been found to have both the desired profile of activity and no hepatotoxicity, when administered po at 50, 100 or 300 mg/kg.Compounds 31, 33 and 36, orally tested at the same doses in the 15-d test, lower triglyceride and VLDL/LDL (very low density lipoprotein / low density lipoprotein) cholesterol levels by 10-33percent and 13-46percent, respectively, and increase HDL-associated cholesterol levels by 10-32percent.These molecules have been chosen for further pharmacological and toxicological evaluations. adenosine / purine / cholesterol / triglyceride / hypolipemic agent

Mono-n-substituted 1,4,7,10-tetraazacyclododecane derivatives, process for their production and pharmaceutical agents containing these derivatives

Tetraazacyclododecane compounds of general formula I STR1 in which E and Q are defined herein and their salts with inorganic and/or organic bases, amino acids or amino acid amides are valuable pharmaceutical agents.

METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS

A method for the treatment of prophylaxis of cardiac disorders in a mammal, comprising administering to such mammal a short-acting β-blocking compound of the formula: STR1 wherein R may be lower alkyl, aryl, or aralkyl; n may be an integer from 0 to about 10; x may be an integer from 1 to 3; Ar may be substituted or unsubstituted aromatic; R. sub.1 may be lower alkyl, or aralkyl; and pharmaceutically accepted salts thereof. Novel compounds possessing short-acting β-adrenergic blocking activity are also disclosed.

Ultra-Short-Acting β-Adrenergic Receptor Blocking Agents. 2. (Aryloxy)propanolamines Containing Esters on the Aryl Function

Several short-acting β-adrenergic receptor blocking agents have been prepared by incorporating ester functions into the aryl portion of certain (aryloxy)propanolamine systems.In particular, methyl 3-phenyl>propionate hydrochloride (ASL-8052) was found to be a moderately potent, cardioselective compound with a short duration of action when determined in in vivo canine models.